{
  "pmcid": "3085934",
  "sha256": "3d8bc5b7b23effba5f05b48a313096c320881f8ebcf97eb476499e8396bea181",
  "timestamp_utc": "2025-11-09T23:47:20.074066+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.255883259911897,
    "reading_ease": 13.070697136563894,
    "word_count": 227
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "This study investigates the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy in patients with resected pancreatic adenocarcinoma."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Conducted as a single-institution phase II randomised controlled trial, 60 patients with resected pancreatic adenocarcinoma were enrolled."
      },
      "Participants": {
        "score": 2,
        "evidence": "60 patients with resected pancreatic adenocarcinoma were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either GM-CSF-based immunotherapy or standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the safety and efficacy of a granulocyte-macrophage colony-stimulating factor (GM-CSF)-based immunotherapy in patients with resected pancreatic adenocarcinoma."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was disease-free survival, assessed over a median follow-up of 24.8 months."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not implemented."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "60 patients with resected pancreatic adenocarcinoma were enrolled."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The median disease-free survival was 17.3 months (95% CI, 14.6–22.8), and the median overall survival was 24.8 months (95% CI, 21.2–31.6)."
      },
      "Harms": {
        "score": 1,
        "evidence": "The immunotherapy was well tolerated, with no severe adverse events reported."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Trial registration number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source of funding]."
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}